EP2051732A4 - DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR - Google Patents

DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR

Info

Publication number
EP2051732A4
EP2051732A4 EP07784988A EP07784988A EP2051732A4 EP 2051732 A4 EP2051732 A4 EP 2051732A4 EP 07784988 A EP07784988 A EP 07784988A EP 07784988 A EP07784988 A EP 07784988A EP 2051732 A4 EP2051732 A4 EP 2051732A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
treatment
methods
metabolic disorders
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07784988A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2051732A1 (en
Inventor
Mark Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diamedica Therapeutics Inc
Original Assignee
Diamedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamedica Inc filed Critical Diamedica Inc
Publication of EP2051732A1 publication Critical patent/EP2051732A1/en
Publication of EP2051732A4 publication Critical patent/EP2051732A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21035—Tissue kallikrein (3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07784988A 2006-07-26 2007-07-26 DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR Withdrawn EP2051732A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82037906P 2006-07-26 2006-07-26
US90982907P 2007-04-03 2007-04-03
PCT/CA2007/001321 WO2008011713A1 (en) 2006-07-26 2007-07-26 Methods of diagnosis and treatment for metabolic disorders

Publications (2)

Publication Number Publication Date
EP2051732A1 EP2051732A1 (en) 2009-04-29
EP2051732A4 true EP2051732A4 (en) 2009-10-21

Family

ID=38981091

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07784988A Withdrawn EP2051732A4 (en) 2006-07-26 2007-07-26 DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR

Country Status (5)

Country Link
US (2) US20100008899A1 (https=)
EP (1) EP2051732A4 (https=)
JP (2) JP2009544630A (https=)
CA (1) CA2659012A1 (https=)
WO (1) WO2008011713A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9000134B2 (en) * 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
EP2182978A4 (en) * 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
US20110150781A1 (en) * 2008-07-25 2011-06-23 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
EP2411042A4 (en) * 2009-03-25 2012-12-12 Diamedica Inc Tissue kallikrein for the treatment of pancreatic cell dysfunction
EP2720703A4 (en) * 2011-06-17 2015-07-22 Univ Johns Hopkins METHOD FOR INCREASING INSULIN SENSITIVITY AND TREATING DIABETES
CN103424496B (zh) * 2012-05-24 2015-02-18 山东绿叶制药有限公司 一种测定痕量艾塞那肽的方法
US20130315891A1 (en) * 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
WO2014059536A1 (en) * 2012-10-15 2014-04-24 Diamedica Inc. Combination of an insulin and tissue kallikrein 1
CN103940935A (zh) * 2013-01-23 2014-07-23 中国农业科学院兰州畜牧与兽药研究所 一种动物血浆中氢溴酸槟榔碱含量的测定方法
WO2017066659A1 (en) * 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Jag1 expression predicts therapeutic response in nash
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216306A1 (en) * 2001-06-06 2003-11-20 Edris Sabbadini Therapeutic uses of glandular kallikrein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2657382A1 (de) * 1976-12-17 1978-06-29 Thera Ges Fuer Patente Orales antidiabetikmittel
DE2658984C2 (de) * 1976-12-27 1983-08-18 Thera Gesellschaft für Patentverwertung mbH, 8036 Herrsching Injizierbare Insulinpräparate
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5403486A (en) * 1991-12-31 1995-04-04 Baker Hughes Incorporated Accelerator system in a centrifuge
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216306A1 (en) * 2001-06-06 2003-11-20 Edris Sabbadini Therapeutic uses of glandular kallikrein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity", DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON, GB, vol. 20, no. 4, 7 July 2004 (2004-07-07), pages 288 - 297, XP009122488, ISSN: 1520-7552 *
JAFFA AYAD A ET AL: "Plasma prekallikrein: A risk marker for hypertension and nephropathy in type 1 diabetes", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 52, no. 5, 1 May 2003 (2003-05-01), pages 1215 - 1221, XP009122470, ISSN: 0012-1797 *
MANTO A ET AL: "Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 36, no. 5, 1 May 1993 (1993-05-01), pages 423 - 427, XP009122471, ISSN: 0012-186X *
ROTHSCHILD A M ET AL: "Increased kininogen levels observed in plasma of diabetic patients are corrected by the administration of insulin", HORMONE AND METABOLIC RESEARCH, vol. 31, no. 5, May 1999 (1999-05-01), pages 326 - 328, XP009122509, ISSN: 0018-5043 *
See also references of WO2008011713A1 *

Also Published As

Publication number Publication date
CA2659012A1 (en) 2008-01-31
EP2051732A1 (en) 2009-04-29
JP2013129672A (ja) 2013-07-04
WO2008011713A1 (en) 2008-01-31
JP2009544630A (ja) 2009-12-17
US20130280235A1 (en) 2013-10-24
US20100008899A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
EP2051732A4 (en) DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR
IL258730A (en) Preparations and methods for the treatment of microbial disorders
IL194189A0 (en) Combination treatment of metabolic disorders
SI2182981T1 (sl) Postopki in sestavki za zdravljenje in diagnozo fibroze
IL207360A0 (en) Methods of diagnosing and treating parp - mediated diseases
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
ZA200900734B (en) Combination treatment for metabolic disorders
IL194820A0 (en) Devices and methods for treatment of tissue
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL195203A0 (en) Compounds for the treatment of metabolic disorders
PT2614832T (pt) Diagnóstico de pré-eclâmpsia
PL2056842T3 (pl) Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
ZA200806808B (en) Treatment of stressed patients
IL192852A0 (en) Compounds for the treatment of metabolic disorders
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
GB0608647D0 (en) Methods of diagnosis and treatment
EP2147013A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DEPRESSION AND FEARING
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
ZA200903653B (en) Methods for treatment of cochlear and vestibular disorders
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
GB0709092D0 (en) Diagnosis and method of disease
IL192851A0 (en) Compounds for the treatment of metabolic disorders
IL191887A0 (en) Method for the diagnosis and treatment of cardiovascular diseases
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20090917

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 30/72 20060101ALI20090911BHEP

Ipc: G01N 30/02 20060101ALI20090911BHEP

Ipc: C40B 30/04 20060101ALI20090911BHEP

Ipc: C12Q 1/37 20060101ALI20090911BHEP

Ipc: C12N 9/64 20060101ALI20090911BHEP

Ipc: A61P 3/10 20060101ALI20090911BHEP

Ipc: A61K 45/06 20060101ALI20090911BHEP

Ipc: A61K 38/48 20060101ALI20090911BHEP

Ipc: G01N 33/53 20060101AFI20090911BHEP

17Q First examination report despatched

Effective date: 20100901

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150126